|Publication type:||Article in scientific journal|
|Type of review:||Peer review (publication)|
|Title:||A cost analysis of sorafenib for desmoid tumors|
|Authors:||Johns, Michael S.|
Merritt, William T.
Ford, Candice N.
Lee, William M.
Petrelli, Nicholas J.
Tiesi, Gregory J.
|Published in:||Journal of Oncology Pharmacy Practice|
|Publisher / Ed. Institution:||Sage|
|Subjects:||Desmoid tumor; Cost analysis; Oncology; Sorafenib|
|Subject (DDC):||615: Pharmacology and therapeutics |
616: Internal medicine and diseases
|Abstract:||Introduction: A recent randomized trial demonstrated that sorafenib improved progression free survival (PFS) in patients with desmoid tumors despite many patients experiencing stable disease or spontaneous regression without treatment. Utilizing these trial data, we performed a cost analysis of sorafenib efficacy through two years of treatment. Methods: Current Medicare Part D rates for sorafenib were utilized (dose 400 mg/day, cost $309/day). Annual costs per progression and objective response were calculated. Radiologic progression and response were defined using RECIST criteria. Patients with disease progression were separately analyzed in two groups: both clinical and radiologic (CAR), and radiologic alone. Results: 84 previously randomized patients were analyzed (placebo: 35, sorafenib: 49). At one year, sorafenib was associated with a 43% absolute risk reduction (ARR) of CAR progression and number-needed-to-treat (NNT) of 2.3 patients/year, costing $259,406. At two years, ARR was 48% and NNT of 2.1 patients/year, costing $473,697. When evaluating only patients with RECIST defined radiologic progression, sorafenib patients experienced ARR of 13.9% with NNT 7.2 and estimated costs of $812,052 at one year. Two-year ARR was 17.5% with NNT 5.7 and estimated costs $1,285,052. Sorafenib patients experienced improved RECIST partial response rates at 1 and 2 years of 14.7% and 14.3%, with NNT 6.8 and 6.9, and costs of $766,938 and $1,556,433; respectively. Conclusion: For the treatment of desmoid tumors, Sorafenib led to improved PFS, but at a significant cost per patient. Favorable RECIST outcomes were less likely and costlier. Patients should be informed of possible benefits of treatment versus potential financial burden.|
|Fulltext version:||Published version|
|License (according to publishing contract):||Licence according to publishing contract|
|Departement:||School of Management and Law|
|Organisational Unit:||Institute of Wealth & Asset Management (IWA)|
|Appears in collections:||Publikationen School of Management and Law|
Files in This Item:
There are no files associated with this item.
Show full item record
Johns, M. S., Merritt, W. T., Rhodes, L., Ford, C. N., Thompson, M., Lee, W. M., Sheldon, Y., Petrelli, N. J., & Tiesi, G. J. (2022). A cost analysis of sorafenib for desmoid tumors. Journal of Oncology Pharmacy Practice. https://doi.org/10.1177/10781552221077927
Johns, M.S. et al. (2022) ‘A cost analysis of sorafenib for desmoid tumors’, Journal of Oncology Pharmacy Practice [Preprint]. Available at: https://doi.org/10.1177/10781552221077927.
M. S. Johns et al., “A cost analysis of sorafenib for desmoid tumors,” Journal of Oncology Pharmacy Practice, Feb. 2022, doi: 10.1177/10781552221077927.
Johns, Michael S., et al. “A Cost Analysis of Sorafenib for Desmoid Tumors.” Journal of Oncology Pharmacy Practice, Feb. 2022, https://doi.org/10.1177/10781552221077927.
Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.